^
Association details:
| Biomarker: | PRKCB-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
Published date:
12/01/2019
Excerpt:
A 44-year-old Chinese male smoker presented to our hospital for a cough that had persisted for 1 month….EML4-ALK (E6:A20) and PRKCB-ALK (P2:A18) double ALK fusion were identified...This patient with double-ALK fusion was sensitive to crizotinib and a novel PRKCB-ALK fusion was detected.
DOI:
10.1016/j.jtho.2019.07.021
